Adjuvant Chemotherapy May Be Unnecessary for Ypt0-2N0 Gastric Cancer Patients after Neoadjuvant Chemotherapy and Curative Gastrectomy.
Xinxin Shao,Fuhai Ma,Wenzhe Kang,Jianping Xiong,Haitao Hu,Weikun Li,Yibin Xie,Yantao Tian
DOI: https://doi.org/10.1097/cm9.0000000000002682
IF: 6.133
2023-01-01
Chinese Medical Journal
Abstract:To the Editor: Gastric cancer (GC) is the sixth most common type of cancer and the third most common cause of cancer-related deaths worldwide.[1] Due to the lack of typical clinical symptoms in the early stage of GC, most patients have advanced-stage disease at the time of initial treatment and have a poor prognosis. The rate of radical resection is low. Even after radical resection, recurrence or death occurs in 50% to 90% of patients, and the 5-year overall survival (OS) rate is less than 30%.[2] Therefore, various multimodal strategies, which would presumably reduce the risk of cancer recurrence and improve survival, are being explored to eliminate any residual tumors and micro-metastases. Neoadjuvant chemotherapy (NAC) followed by surgery is recommended as the standard of care for patients with localized resectable GC, based on significantly improved OS rates in patients observed in randomized controlled trials.[2] Although NAC combined with adjuvant chemotherapy has been included in the National Comprehensive Cancer Network (NCCN) guidelines as an optional treatment for prospective resectable advanced GC cases,[2] regardless of the postoperative pathological stage, the benefit of adjuvant chemotherapy remains controversial, and it is unclear whether adjuvant chemotherapy can be omitted in patients with a good response to NAC and curative surgery. According to the current guidelines, adjuvant chemotherapy is not recommended for patients with stage I GC who have undergone D2 radical gastrectomy without receiving NAC.[3] Previous study showed that ypN status played the major role in predicting OS.[4] Patients with ypT0-2N0 disease who have undergone NAC and radical gastrectomy are expected to have favorable oncological outcomes and a good response to treatment.[5] However, these guidelines do not address whether adjuvant chemotherapy should be administered to patients who show downstaging of ypT0-2N0 disease after NAC. Therefore, in this single-center, retrospective study, we aimed to evaluate whether adjuvant chemotherapy was associated with improved outcomes in patients with ypT0-2N0 GC who had undergone NAC and curative gastrectomy. We retrieved patient information from a prospectively maintained database containing electronic medical records of GC patients who underwent gastrectomy at our hospital. The study was conducted following the tenets of the Helsinki Declaration of 1975, and the retrospective protocol was approved by the Ethics Committee of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (No. 20/086-2282). Consecutive patients with GC who underwent NAC and radical gastrectomy between January 2011 and December 2019 were included on meeting the following criteria: (1) histologically proven primary gastric adenocarcinoma, (2) administration of NAC, (3) R0 gastrectomy with D2 lymphadenectomy, and (4) pathological classification of ypT0-2N0 disease. The exclusion criteria were (1) preoperative chemoradiotherapy or radiotherapy, (2) distant metastasis, (3) other co-occurring malignancies, and (4) gastric remnant carcinoma. We divided patients into two groups based on whether they had received adjuvant chemotherapy. All patients underwent clinical tumor staging assessment using computed tomography before NAC, according to the eighth edition of American Joint Committee on Cancer (AJCC) staging system. NAC regimens included doublet agents (cisplatin/oxaliplatin + 5-fluorouracil/capecitabine/S-1, paclitaxel + cisplatin/capecitabine/S-1), triplet agents (paclitaxel + cisplatin/oxaliplatin + 5-fluorouracil/capecitabine/S-1), and other fluoropyrimidine/platinum-based regimens. The adjuvant chemotherapy regimens were the same as the NAC regimens in most patients. In the resected specimens, pathological response to NAC was assessed by two independent pathologists using the Mandard tumor regression grade scoring system. OS and disease-free survival (DFS) intervals were calculated, and telephonic interviews were conducted for follow-up. Categorical and continuous variables were analyzed using Fisher's exact or chi-squared tests and the Mann–Whitney U test or Student's t-test, respectively. Survival curves were plotted using the Kaplan–Meier method, and log-rank tests were used to compare the differences between the groups. Univariate and multivariate Cox regression analyses were performed to identify variables impacting the prognosis of the disease (OS and DFS) and to investigate the predictive ability and interaction effects between covariates. Factors with P <0.200 in the univariate analysis were included in the multivariate regression. Differences were considered statistically significant at P <0.050. All statistical analyses were performed using IBM SPSS software (version 22.0, IBM Corp., Armonk, NY, USA). Of the 125 eligible patients, postoperative adjuvant chemotherapy was administered in 95 (76.0%) and omitted in 30 (24.0%) [Supplementary Tables 1 and 2, https://links.lww.com/CM9/B544]. In the univariate analyses, clinical stage T4b, tumor bed size of the histologic specimen, perineural invasion, and examined lymph nodes (<16) were potential risk factors. In the multivariate Cox model, the type of surgery (subtotal vs. total), tumor bed size of the histologic specimen, and perineural invasion were significant prognostic factors for OS [Supplementary Table 3, https://links.lww.com/CM9/B544]. Survival curves according to adjuvant chemotherapy status were shown in Figure 1. In patients who received triplet or doublet agents, the NAC regimen was not associated with improved OS and DFS, regardless of the adjuvant chemotherapy [Supplementary Figure 1, https://links.lww.com/CM9/B543].Figure 1: Survival curves of the eligible patients according to adjuvant chemotherapy status. OS of (A) all patients and patients with (B) ypT0N0 and (C) ypT1-2N0 disease. DFS of(D) all patients and patients with (E) ypT0N0 and (F) ypT1-2N0 disease. DFS: Disease-free survival; OS: Overall survival.We observed that adjuvant chemotherapy provided no long-term benefit for patients with ypT0-2N0 GC. There were no differences in OS or DFS rates between the two groups based on adjuvant chemotherapy status. Subgroup analyses showed no significant differences in the 5-year DFS and OS rates between patients with ypT0N0 and ypT1-2N0 disease. Univariate and multivariate analyses also showed no association between prognosis and postoperative adjuvant chemotherapy. Thus, adjuvant chemotherapy may not be necessary for patients with ypT0-2N0 GC who have undergone NAC and curative gastrectomy. In the future, a randomized controlled trial is warranted to confirm this study's conclusion. The limitations of the study include probable selection bias leading to limited statistical power, non-standardized NAC regimens and indications, and short follow-up period that might have caused the under-reporting of deaths. Acknowledgments We would like to express our gratitude to Zhikai Zhu from Center for Big Data, National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, for providing statistical guidance and support for this paper. Funding This work was supported by grant from National Natural Science Foundation of China (No. 82072734). Conflicts of interest None.